These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 34768921)

  • 1. PDK1 Inhibitor BX795 Improves Cisplatin and Radio-Efficacy in Oral Squamous Cell Carcinoma by Downregulating the PDK1/CD47/Akt-Mediated Glycolysis Signaling Pathway.
    Pai S; Yadav VK; Kuo KT; Pikatan NW; Lin CS; Chien MH; Lee WH; Hsiao M; Chiu SC; Yeh CT; Tsai JT
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768921
    [No Abstract]   [Full Text] [Related]  

  • 2. CD47-SIRPα Signaling Induces Epithelial-Mesenchymal Transition and Cancer Stemness and Links to a Poor Prognosis in Patients with Oral Squamous Cell Carcinoma.
    Pai S; Bamodu OA; Lin YK; Lin CS; Chu PY; Chien MH; Wang LS; Hsiao M; Yeh CT; Tsai JT
    Cells; 2019 Dec; 8(12):. PubMed ID: 31861233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PER2 binding to PDK1 enhances the cisplatin sensitivity of oral squamous cell carcinoma through inhibition of the AKT/mTOR pathway.
    Zheng H; Yu W; Ren J; Tang H; Li H; Zhang Z; Yin S; Yang K
    Cell Signal; 2024 Oct; 122():111327. PubMed ID: 39079621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated PDK1 Expression Drives PI3K/AKT/MTOR Signaling Promotes Radiation-Resistant and Dedifferentiated Phenotype of Hepatocellular Carcinoma.
    Bamodu OA; Chang HL; Ong JR; Lee WH; Yeh CT; Tsai JT
    Cells; 2020 Mar; 9(3):. PubMed ID: 32197467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BX795, a TBK1 inhibitor, exhibits antitumor activity in human oral squamous cell carcinoma through apoptosis induction and mitotic phase arrest.
    Bai LY; Chiu CF; Kapuriya NP; Shieh TM; Tsai YC; Wu CY; Sargeant AM; Weng JR
    Eur J Pharmacol; 2015 Dec; 769():287-96. PubMed ID: 26607461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CMTM6 drives cisplatin resistance by regulating Wnt signaling through the ENO-1/AKT/GSK3β axis.
    Mohapatra P; Shriwas O; Mohanty S; Ghosh A; Smita S; Kaushik SR; Arya R; Rath R; Das Majumdar SK; Muduly DK; Raghav SK; Nanda RK; Dash R
    JCI Insight; 2021 Feb; 6(4):. PubMed ID: 33434185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Malic Enzyme 1 Is Associated with Tumor Budding in Oral Squamous Cell Carcinomas.
    Nakashima C; Kirita T; Yamamoto K; Mori S; Luo Y; Sasaki T; Fujii K; Ohmori H; Kawahara I; Mori T; Goto K; Kishi S; Fujiwara-Tani R; Kuniyasu H
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32998265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. San-Zhong-Kui-Jian-Tang Exerts Antitumor Effects Associated With Decreased Cell Proliferation and Metastasis by Targeting ERK and the Epithelial-Mesenchymal Transition Pathway in Oral Cavity Squamous Cell Carcinoma.
    Hsu PY; Chen JL; Kuo SL; Wang WL; Jan FW; Yang SH; Yang CY
    Integr Cancer Ther; 2022; 21():15347354221134921. PubMed ID: 36404765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer-derived IgG involved in cisplatin resistance through PTP-BAS/Src/PDK1/AKT signaling pathway.
    Wang LM; Gan YH
    Oral Dis; 2021 Apr; 27(3):464-474. PubMed ID: 32730654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by sunppressing miR-184 expression.
    Fang Z; Zhao J; Xie W; Sun Q; Wang H; Qiao B
    Cancer Med; 2017 Dec; 6(12):2897-2908. PubMed ID: 29125238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bromodomain-containing protein 4 inhibition improves the efficacy of cisplatin and radiotherapy in oral squamous cell carcinoma by suppressing programmed cell death-ligand 1 expression.
    Ren J
    Basic Clin Pharmacol Toxicol; 2024 Feb; 134(2):272-283. PubMed ID: 38014458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nitrate increases cisplatin chemosensitivity of oral squamous cell carcinoma via REDD1/AKT signaling pathway.
    Feng Y; Cao X; Zhao B; Song C; Pang B; Hu L; Zhang C; Wang J; He J; Wang S
    Sci China Life Sci; 2021 Nov; 64(11):1814-1828. PubMed ID: 34542810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of Histone Deacetylase Inhibitor Sensitivity in Combination with Cyclin-Dependent Kinase Inhibition for the Treatment of Oral Squamous Cell Carcinoma.
    Zhao B; Huang Z; Qin Z; Li Y; Wang T; Wang L; Zhou W; Yu C; Wang X; Yang S; Fan Y; Xiang R
    Cell Physiol Biochem; 2019; 53(1):141-156. PubMed ID: 31237760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PDK1 Inhibitor GSK-470 Exhibits Potent Anticancer Activity in a Pheochromocytoma PC12 Cell Tumor Model via Akt/mTOR Pathway.
    Zhang X; Zhong S
    Anticancer Agents Med Chem; 2020; 20(7):828-833. PubMed ID: 32188393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HOXA1 silencing inhibits cisplatin resistance of oral squamous cell carcinoma cells via IκB/NF-κB signaling pathway.
    Zhu R; Mao Y; Xu X; Li Y; Zheng J
    Anticancer Drugs; 2024 Jul; 35(6):492-500. PubMed ID: 38477942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of PER2 Promotes Tumor Progression by Enhancing Glycolysis via the Phosphatidylinositol 3-Kinase/Protein Kinase B Pathway in Oral Squamous Cell Carcinoma.
    Long W; Gong X; Yang Y; Yang K
    J Oral Maxillofac Surg; 2020 Oct; 78(10):1780.e1-1780.e14. PubMed ID: 32615095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crosstalk between Raf-MEK-ERK and PI3K-Akt-GSK3β signaling networks promotes chemoresistance, invasion/migration and stemness via expression of CD44 variants (v4 and v6) in oral cancer.
    Kashyap T; Pramanik KK; Nath N; Mishra P; Singh AK; Nagini S; Rana A; Mishra R
    Oral Oncol; 2018 Nov; 86():234-243. PubMed ID: 30409306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blocking circ-CNST suppresses malignant behaviors of osteosarcoma cells and inhibits glycolysis through circ-CNST-miR-578-LDHA/PDK1 ceRNA networks.
    Hu R; Chen S; Yan J
    J Orthop Surg Res; 2021 May; 16(1):300. PubMed ID: 33962616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined inhibition of pyruvate dehydrogenase kinase 1 and lactate dehydrogenase a induces metabolic and signaling reprogramming and enhances lung adenocarcinoma cell killing.
    Zhou Y; Guo Y; Ran M; Shan W; Granchi C; Giovannetti E; Minutolo F; Peters GJ; Tam KY
    Cancer Lett; 2023 Nov; 577():216425. PubMed ID: 37805163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting CD47 Inhibits Tumor Development and Increases Phagocytosis in Oral Squamous Cell Carcinoma.
    Ye XJ; Yang JG; Tan YQ; Chen XJ; Zhou G
    Anticancer Agents Med Chem; 2021; 21(6):766-774. PubMed ID: 32748759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.